Spring allergy season is just around the corner. And for sufferers, a new treatment, Clarinex-D� 24 Hour extended release tablets combines desloratadine 5 mg and pseudoephedrine sulfate USP 240 mg, bringing together an antihistamine and decongestant to help relieve the symptoms of seasonal allergies, including nasal congestion.
The U.S. Food and Drug Administration has approved Clarinex-D� 24 Hour extended release tablets for the relief of seasonal outdoor allergy symptoms, including nasal congestion, in patients 12 years of age and older. Available this April in time for spring allergy season, this will be the only once-daily prescription antihistamine and decongestant combination treatment on the market to provide 24-hour relief of nasal and non-nasal allergy symptoms. Doctor William Lumry, an allergy and asthma specialist in Dallas, Texas:
"Patients are most bothered by their allergy symptoms in the morning, when they wake up. If they have a 24-hour medication, their symptoms can be controlled throughout the day, the night and when they get up in the morning."
According to a survey of a thousand adults with allergies, 83 percent said they experience symptoms in the morning and more people indicated they suffer from nasal congestion, compared to other allergy symptoms, when they first wake up. Seasonal allergies affect an estimated 36 million people in the U.S. For more information, visit w-w-w- dot-allergyrelief-dot-com.
CLARINEX-D� 24 Hour Extended Release Tablets is contraindicated in patients with narrow-angle glaucoma, urinary retention, severe hypertension, or severe coronary artery disease and in patients receiving monoamine oxidase (M-A-O) inhibitor therapy or within 14 days of stopping such treatment. It should generally be avoided in patients with hepatic insufficiency. It should also be used with caution in patients with hypertension, diabetes mellitus, ischemic heart disease, increased intraocular pressure, hyperthyroidism, renal impairment, or prostatic hypertrophy. Care should be taken in the concomitant administration of other sympathomimetic amines because combined effects on the cardiovascular system may be harmful to the patient. The most commonly reported adverse events for CLARINEX-D� 24 Hour Extended Release Tablets compared with desloratadine alone are dry mouth (8 percent versus 2 percent), headache (6 percent versus 5 percent), insomnia (5 percent versus 1 percent), fatigue (3 percent versus 3 percent), pharyngitis (3 percent versus 2 percent), and somnolence (3 percent versus 2 percent).
CLICK HERE to download a transcript of this story:
https://www.cpwire.com/click.asp?feature=https://216.86.33.66/allerg.doc
CLICK HERE to download a multimedia (MP3) file of this story:
https://www.cpwire.com/click.asp?feature=https://216.86.33.66/allerg.mp3
